FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasimigton,	D.O.	20070

STATEMENT OF CHANGES IN BENEFICIAL O	WNERSHIP
--------------------------------------	----------

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average burden										
- 1	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>JOHNSON DAVID LEE</u>				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol Caribou Biosciences, Inc. [CRBU]					(Ch	elationship of the contract of	cable)	Person(s) to Iss 10% Ov		
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/20/2024							Officer below)	(give title	Other (sbelow)	specify
C/O CARIBOU BIOSCIENCES, INC. 2929 7TH STREET, SUITE 105				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) BERKEI	LEY C.	A	94710			401 =	4					Form f Persor		han One Repo	rting
(City)	(S	tate)	(Zip)] Chec	k this box	to ind	Transac icate that a trar defense condi	saction was n	nade pursua			n or written pla	n that is intende	I to
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
Date			. Transactio ate Month/Day/Y	Execution Date,		Code (Instr. 5)				5. Amou Securitie Beneficia Owned F Reported	s Form		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amount	(A) or (D) Price		Transact (Instr. 3	ion(s)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		ransaction ode (Instr.) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to purchase Common Stock	\$6.81	02/20/2024		A		39,500		(1)	02/19/2034	Common Stock	39,500	\$0	39,500	D	

Explanation of Responses:

1. One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Remarks:

/s/ Barbara G. McClung, as attorney-in-fact

02/22/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.